TherapeuticsMD Inc. (TXMD)

6.13
0.01 0.16
NASDAQ : Health Technology
Prev Close 6.14
Open 6.16
Day Low/High 6.10 / 6.23
52 Wk Low/High 4.34 / 7.66
Volume 1.59M
Avg Volume 2.26M
Exchange NASDAQ
Shares Outstanding 233.50M
Market Cap 1.47B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The China Trade: Cramer's 'Mad Money' Recap (Friday 9/7/18)

The China Trade: Cramer's 'Mad Money' Recap (Friday 9/7/18)

Jim Cramer says the president's predictability on trade makes it clear: Good news for the U.S. economy has become bad news for stocks.

Urban Outfitters, CenturyLink, Avnet: 'Mad Money' Lightning Round

Urban Outfitters, CenturyLink, Avnet: 'Mad Money' Lightning Round

Jim Cramer weighs in on Urban Outfitters, CenturyLink, Avnet, Pitney Bowes, UnitedHealth Group, General Mills, TherapeuticsMD and more.

TherapeuticsMD To Present At 13th Annual Wells Fargo Securities Healthcare Conference

TherapeuticsMD To Present At 13th Annual Wells Fargo Securities Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will present at the 13 th Annual Wells Fargo Securities Healthcare Conference being held on September 5-6, 2018 in Boston.

TherapeuticsMD Announces FDA Approval Of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) For Birth Control

TherapeuticsMD Announces FDA Approval Of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) For Birth Control

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the United States (U.

TherapeuticsMD Announces Closing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering Of Common Stock

TherapeuticsMD Announces Closing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering Of Common Stock

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its previously announced $65 million underwritten public offering of common stock, at a price to the public of $5.

TherapeuticsMD Announces Pricing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering For Aggregate Gross Proceeds Of $85 Million

TherapeuticsMD Announces Pricing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering For Aggregate Gross Proceeds Of $85 Million

TherapeuticsMD, Inc. (NASDAQ: TXMD) today announced the pricing of its previously announced $65 million underwritten public offering of common stock at a price to the public of $5.

TherapeuticsMD Licenses Population Council's Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System

TherapeuticsMD Licenses Population Council's Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it has entered into an exclusive license agreement with the Population Council to commercialize its investigational segesterone acetate/ ethinyl estradiol...

Knight Therapeutics And TherapeuticsMD Announce Strategic Partnership

Knight Therapeutics And TherapeuticsMD Announce Strategic Partnership

Knight Therapeutics Inc. (TSX: GUD) (" Knight"), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc.

TherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering And Concurrent $20 Million Registered Direct Offering Of Common Stock

TherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering And Concurrent $20 Million Registered Direct Offering Of Common Stock

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the launch of a $65 million underwritten public offering and a concurrent $20 million registered direct offering to a strategic investor of shares of its common stock.

TherapeuticsMD Announces Second Quarter 2018 Financial Results

TherapeuticsMD Announces Second Quarter 2018 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended June 30, 2018.

TherapeuticsMD To Report Second Quarter 2018 Financial Results On July 30, 2018

TherapeuticsMD To Report Second Quarter 2018 Financial Results On July 30, 2018

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will report its second quarter 2018 financial results on Monday, July 30, 2018, before the opening of the U.

A Very Odd Day for the Market

For the Russell to be down over one percent and breadth to be negative by 100 issues is highly unusual.

Interesting TXMD Put And Call Options For October 19th

Interesting TXMD Put And Call Options For October 19th

Investors in TherapeuticsMD Inc saw new options begin trading today, for the October 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 91 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of TXMD August 17th Options Trading

First Week Of TXMD August 17th Options Trading

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD Announces Draw Down Of $75 Million Under Term Loan With MidCap Financial

TherapeuticsMD Announces Draw Down Of $75 Million Under Term Loan With MidCap Financial

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company has completed the first draw down of $75 million under its previously announced $200 million term loan facility with MidCap Financial, managed...

TherapeuticsMD To Present At Goldman Sachs 39th Annual Global Healthcare Conference

TherapeuticsMD To Present At Goldman Sachs 39th Annual Global Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will present at the Goldman Sachs 2018 Global Healthcare Conference being held on June 12-14, 2018 in Rancho Palos Verdes, CA.

TherapeuticsMD Announces Multiple Presentations At The International Menopause Society's 16th World Congress

TherapeuticsMD Announces Multiple Presentations At The International Menopause Society's 16th World Congress

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the schedule of seven presentations at the International Menopause Society's 16 th World Congress on Menopause related to clinical data for Imvexxy™ (estradiol...

TherapeuticsMD To Present At Jefferies 2018 Healthcare Conference

TherapeuticsMD To Present At Jefferies 2018 Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will present at the Jefferies 2018 Healthcare Conference being held on June 5-8, 2018.

TherapeuticsMD Announces Clinical Abstract At The 2018 ASCO Annual Meeting

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the availability of clinical data from the REJOICE trial for IMVEXXY™ (estradiol vaginal inserts) (formerly TX-004HR).

TherapeuticsMD Comments On Media Reports Regarding TX-004HR

TherapeuticsMD Comments On Media Reports Regarding TX-004HR

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today commented on media reports that TX-004HR, the company's investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal...

Interesting TXMD Put And Call Options For July 20th

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD Announces Investor And Analyst Day On June 4

TherapeuticsMD Announces Investor And Analyst Day On June 4

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the Company will host an Investor and Analyst Day on Monday, June 4, 2018, in New York City.

TherapeuticsMD Announces First Quarter 2018 Financial Results

TherapeuticsMD Announces First Quarter 2018 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended March 31, 2018.

TherapeuticsMD To Host First Quarter Financial Results Conference Call And Webcast On May 3

TherapeuticsMD To Host First Quarter Financial Results Conference Call And Webcast On May 3

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss its first quarter financial and business results on Thursday, May 3.

First Week Of TXMD December 21st Options Trading

Investors in TherapeuticsMD Inc saw new options become available this week, for the December 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

TherapeuticsMD Announces Expansion Of Board Of Directors

TherapeuticsMD Announces Expansion Of Board Of Directors

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the appointment of Jane F.

TheStreet Quant Rating: D (Sell)